180 related articles for article (PubMed ID: 30517530)
41. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
[TBL] [Abstract][Full Text] [Related]
42. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
[TBL] [Abstract][Full Text] [Related]
43. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
45. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
[TBL] [Abstract][Full Text] [Related]
46. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
[TBL] [Abstract][Full Text] [Related]
47. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil.
de Camargo Ferreira E Vasconcellos E; de Oliveira Schubach A; Valete-Rosalino CM; de Souza Coutinho R; Conceição-Silva F; de Matos Salgueiro M; Rosandiski Lyra M; Soares Moreira J; Azeredo-Coutinho RB; Fernandes Pimentel MI; Roberto Mortari S; de Fátima Madeira M; Pereira Quintella L; Baptista C; de Almeida Marzochi MC
J Am Geriatr Soc; 2010 Mar; 58(3):614-6. PubMed ID: 20398135
[No Abstract] [Full Text] [Related]
48. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
Javadi A; Khamesipour A; Ghoorchi M; Bahrami M; Khatami A; Sharifi I; Eskandari SE; Fekri A; Aflatoonian MR; Firooz A
PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010569. PubMed ID: 35802749
[TBL] [Abstract][Full Text] [Related]
49. The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis.
Radmanesh M; Omidian E
J Dermatolog Treat; 2017 Aug; 28(5):422-425. PubMed ID: 28043177
[TBL] [Abstract][Full Text] [Related]
50. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
52. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
53. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
54. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
56. Interventions to treat cutaneous leishmaniasis in children: A systematic review.
Uribe-Restrepo A; Cossio A; Desai MM; Dávalos D; Castro MDM
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006986. PubMed ID: 30550538
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
58. The successful use of radiofrequency-induced heat therapy for cutaneous leishmaniasis: a review.
David JR
Parasitology; 2018 Apr; 145(4):527-536. PubMed ID: 29536826
[TBL] [Abstract][Full Text] [Related]
59. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
60. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
